Financials data is unavailable for this security.
View more
Year on year Nang Kuang Pharmaceutical Co Ltd had net income fall -43.63% from 352.00m to 198.41m despite a 10.81% increase in revenues from 1.94bn to 2.15bn. An increase in the selling, general and administrative costs as a percentage of sales from 11.79% to 15.37% was a component in the falling net income despite rising revenues.
| Gross margin | 33.14% |
|---|---|
| Net profit margin | 5.28% |
| Operating margin | 6.05% |
| Return on assets | 3.02% |
|---|---|
| Return on equity | 4.77% |
| Return on investment | 4.47% |
More ▼
Cash flow in TWDView more
In 2023, cash reserves at Nang Kuang Pharmaceutical Co Ltd fell by 22.73m. However, the company earned 342.61m from its operations for a Cash Flow Margin of 15.93%. In addition the company used 329.51m on investing activities and also paid 35.77m in financing cash flows.
| Cash flow per share | 2.90 |
|---|---|
| Price/Cash flow per share | 15.35 |
| Book value per share | 22.52 |
|---|---|
| Tangible book value per share | 22.46 |
More ▼
Balance sheet in TWDView more
| Current ratio | 1.21 |
|---|---|
| Quick ratio | 0.6312 |
| Total debt/total equity | 0.1886 |
|---|---|
| Total debt/total capital | 0.1587 |
More ▼
Growth rates in TWD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -13.04% and -43.59%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 4.02% |
|---|---|
| Div growth rate (5 year) | 10.76% |
| Payout ratio (TTM) | 182.53% |
| EPS growth(5 years) | 14.39 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -73.78 |
More ▼
